BRUSSELS, July 1 Belgian biotech company
Innogenetics INNX.BR said on Tuesday it had granted
GlaxoSmithKline (GSK.L) a worldwide, non-exclusive license to
use its technology in cervical cancer vaccine studies.
Innogenetics said it would receive royalties for each test
performed during the studies.
GSK agreed to license Innogenetics' SPF10 primer technology,
the Belgian company said in a statement.
U.S. disease diagnosis firm Gen-Probe Inc (GPRO.O) last
month launched a 215 million euro ($339.3 million) bid for
Innogenetics, trumping an offer from local drugmaker Solvay
(Writing by William Schomberg)